Addiction psychiatry: where we are and challenges in the UK
Anne Anne Lingford-Hughes
International Review of Psychiatry March 31, 2026 DOI: 10.1080/09540261.2026.2627509 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Perspective or opinion piece Peer reviewed |
|---|---|
| Population | UK addiction psychiatry context |
| Topics | Addiction |
| Keywords | Multidisciplinary approach Workforce Mental health Perspective graphical Neuromodulation Behavioral addiction Addiction medicine Psychotherapist Addiction treatment |
| Key points | Argues that addiction psychiatry in the UK faces enduring challenges including under-investment, workforce changes, and stigma, and that emerging treatments such as psychedelics and neuromodulation require larger, better-designed trials in clinically representative populations. |
Abstract
This piece is a personal and evidence-informed perspective on the current status and future direction of addiction psychiatry in the UK, based on my 30 years as a clinical academic addiction psychiatrist. Alcohol and drug addictions are associated with immense burdens to the individual and society, and this is likely to endure. Challenges facing addiction services to overcome include under-investment, changes in workforce composition with less psychiatric input, improving integration with mental and physical health services as well as stigma. Supporting those with addiction requires a multidisciplinary approach and consideration of neurobiological, psychological and social factors. The progress and limitations in treatment development are reviewed, noting that psychological therapies remain the mainstay, while relatively few new pharmacological treatments have become available in recent decades. Emerging approaches, including novel pharmacological targets, psychedelics and neuromodulation show promise but require larger, better-designed trials, particularly in clinically representative populations with polydrug use and comorbid mental illness. Neuroimaging is highlighted as a key tool for understanding mechanisms, identifying biomarkers, and accelerating treatment development. To drive innovation and ultimately improve outcomes for people affected by addiction senior strategic leadership, robust research infrastructure, global collaboration, reduced stigma, and a research-capable workforce is required.
Citations in the library
Cites 15
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder JAMA Psychiatry August 24, 2022
- Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research Journal of Psychoactive Drugs June 1, 1997
- A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial. American Journal of Psychiatry December 2, 2019
- Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder American Journal of Psychiatry January 11, 2022
- Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial EClinicalMedicine March 14, 2025
and 10 more in the library